Background: Sexually transmitted infections (STIs) are a common reason for evaluation in the emergency department (ED). Given the overlapping risk factors for STIs, patients screened for gonorrhea and chlamydia should be tested for syphilis and HIV. Syphilis and HIV testing rates in the ED have been reported to be low. The study objective was to examine whether collaboration between emergency medicine (EM) and infectious disease (ID) providers improved syphilis and HIV testing in the ED.

Methods: A multidisciplinary team of EM and ID providers was formed to identify and address barriers to syphilis and HIV testing in the ED. Syphilis, HIV, chlamydia, and gonorrhea testing and infection rates were calculated and compared during 2 time periods: preintervention (January 1, 2012–December 30, 2017) and postintervention (November 1, 2018–November 30, 2019). We also extracted clinical and laboratory data from patients with positive syphilis and HIV results during the study period.

Results: The most commonly cited barrier to syphilis and HIV testing was concern about follow-up of positive results. Compared with the preintervention period, syphilis and HIV testing rates increased significantly in the postintervention period (incidence rate ratios, 30.70 [P < 0.0001] and 28.99 [P < 0.0001] for syphilis and HIV, respectively). The postintervention period was also associated with a significant increase in the identification of patients with positive syphilis and HIV results (incidence rate ratios, 7.02 [P < 0.0001] and 2.34 [P = 0.03], respectively).

Conclusions: Collaboration between EM and ID providers resulted in a significant increase in syphilis and HIV testing and diagnosis in the ED.

Syphilis and HIV continue to be major public health threats in the United States.1,2 Although the annual incidence of HIV has decreased significantly since the beginning of the HIV epidemic, rates of new HIV infections have remained roughly stable over the past decade, with 37,881 new HIV infections reported in the United States in 2018.3 Unfortunately, HIV infection often goes undiagnosed, with an estimated 1 of every 7 people living with HIV unaware of their diagnosis. This finding has significant public health implications as those who are unaware of their diagnosis may account for up to one-third of all new HIV transmissions in the United States.3 Early diagnosis of HIV and treatment with antiretroviral therapy (ART) has been shown to reduce complications and improve overall morbidity and mortality of the individual.4 In addition, people living with HIV who have sustained viral suppression on ART are effectively unable to transmit the virus to others, so early diagnosis and linkage to care can also have a profound impact on HIV prevention in the community.5

In the case of syphilis, there has been an increased number of reported syphilis cases over the past decade in the United States, with an estimated 115,045 number of reported cases in 2018 including 1306 cases of congenital syphilis.6 Over the past several years, Columbus, Ohio, has been experiencing a significant syphilis outbreak. Between 2013 and 2017, there was a 109% increase in local syphilis rates, with local rates 2 times higher than overall US rates.7 In addition to the known sequelae of syphilis (which can include severe cardiovascular or neurologic complications), studies have shown a link between a diagnosis of syphilis and future risk of HIV infection.7

Emergency departments (EDs) are often the only point of health care access for many individuals at risk for sexually transmitted infections (STIs). Emergency department visits for STI exposures or STI-related complaints are very common.8 Although most patients who request STI testing or who present with STI-related complaints in the ED are screened for chlamydia and gonorrhea, rates of HIV and syphilis testing are low.9 In the case of HIV, previously reported barriers to testing in the ED include perceived lack of time, unfamiliarity with screening guidelines, provider discomfort in addressing positive results, concerns about adequate follow-up, and misperceptions regarding a specific individual’s risks.10–12 For syphilis, a commonly cited barrier to testing in the ED include concerns about patient follow-up.13 Given the importance of early diagnosis and treatment of syphilis and HIV, interventions focused on decreasing barriers to testing are needed.

A multidisciplinary team of emergency medicine (EM) and infectious disease (ID) providers was formed to identify and address barriers to syphilis and HIV testing in the ED. The primary objective of this study was to measure rates of testing and diagnosis for syphilis and HIV in a community-based ED associated with a large academic medical center before and after the implementation of a multifaceted and collaborative intervention. The ED is located in an urban area in Columbus, Ohio, that serves a large minority population.14

A Collaborative Intervention Between Emergency Medicine and Infectious Diseases to Increase Syphilis and HIV Screening in the Emergency Department

Ashley A. Lipps, MD,* Jose A. Bazan, DO,** Mark E. Lustberg, MD, PhD,* Mohammad Mahdee Sobhanie, MD,* Brandon Pollak, MD,§ Kushal Nandam, MD,§ Susan L. Koletar, MD,* Sommer Lindsey, MD,§ Michael Dick, MD,§ and Carlos Malvestutto, MD, MPH*
population with high rates of poverty and limited access to health care (approximately 50% of patients covered by Medicaid). It is located in direct proximity to 4 of the zip codes with the highest rates of syphilis in the county and in 1 of the 48 counties identified by the US Department of Health and Human Services as a region of high HIV incidence as part of the “Ending the HIV Epidemic” initiative.14,15

**MATERIALS AND METHODS**

After the formation of the multidisciplinary team of EM and ID providers, an anonymous survey was distributed to EM providers in order to identify barriers to syphilis and HIV testing in the ED during the first phase of the intervention. Educational materials, which included a review of the most recent Centers for Disease Control and Prevention sexually transmitted disease treatment guidelines were provided as a resource for EM providers.16 The second phase involved the generation of automated treatment guidelines were provided as a resource for EM providers in order to identify barriers to syphilis and HIV testing during the preintervention period (328 tests/month vs. 329 tests/month: IRR, 0.97; 95% confidence interval [CI], 0.93–1.01; \( P = 0.141 \)). The postintervention period was associated with an increased likelihood of a positive gonorrhea test result (IRR, 1.32; 95% CI, 1.13–1.54; \( P < 0.001 \)), but not a positive chlamydia test result (IRR, 0.99; 95% CI, 0.89–1.10; \( P = 0.81 \)). There was also an increase in extragenital testing of chlamydia and gonorrhea during the postintervention period (160 oral tests and 32 rectal tests) compared with the preintervention period in which there was almost no extragenital testing for gonorrhea or chlamydia performed.

Compared with the preintervention period, the postintervention period was associated with an increased rate of syphilis testing (4 tests/month vs. 108 tests/month: IRR, 30.70; 95% CI, 26.8–35.2; \( P < 0.0001 \)). It was also associated with an increased identification of individuals with a positive syphilis test result (0.63 tests/month vs. 4.4 tests/month: IRR, 7.02; 95% CI, 4.66–10.61; \( P < 0.0001 \)) and an increase in the number of people who were treated for syphilis (0.49 people/month vs. 1.1 people/month: IRR, 2.22; 95% CI, 1.10–4.22; \( P = 0.02 \)). Three (5.3%) of 57 patients with positive syphilis antibody test results were identified as having primary or secondary syphilis. All 3 patients received appropriate treatment. Twenty-six (46%) of 57 patients with positive syphilis antibody test results were identified as having latent syphilis. Six (23.1%) of the 26 patients with late latent syphilis completed a full course of treatment, 5 (19.2%) of the 26 patients with late latent syphilis completed partial treatment, and 15 (57.7%) of the 26 patients with late latent syphilis did not receive any treatment because they were lost to follow-up. Twenty-eight patients had syphilis results that were consistent with a known previously treated infection, and 8 additional patients were considered to have false-positive screening results (defined as having a reactive syphilis antibody test but nonreactive RPR and TP-PA). Table 1 shows the characteristics of patients diagnosed with syphilis during the postintervention period. Of the 57 patients in the postintervention period with positive syphilis test results, 50 were HIV negative and 23 of those had an outpatient referral placed for HIV preexposure prophylaxis (PrEP).

Compared with the preintervention period, the postintervention period was associated with an increase in the rate of HIV testing (4 tests/month vs. 125 tests/month: IRR, 28.39; 95% CI, 25.73–32.67; \( P < 0.0001 \)). The intervention was also associated with an increased frequency of positive HIV test results (0.36 tests/month vs. 0.85 tests/month: IRR, 2.34; 95% CI, 1.4–4.91; \( P = 0.03 \)). Of the 11 positive HIV test results documented during the postintervention period, 7 were from patients who had a new diagnosis. The remaining 4 positive HIV test results were from patients who had a previous diagnosis, although 2 of them were not in care and were not taking any ART. Follow-up of the 2 patients who were out of care was not available. All new HIV diagnoses were in men with a median age of 32 years (range, 27–56 years). Five of the 7 patients with new HIV diagnosis were rapidly linked...
to care and started on ART (mean time to evaluation by an ID provider was 5.4 days; range, 1–15 days). Table 2 shows the characteristics of patients with newly diagnosed HIV infection who were identified during the postintervention time period.

**DISCUSSION**

The ED plays an important role in STI testing and treatment. Although patients who are screened for STIs in the ED are routinely tested for chlamydia and gonorrhea, the same does not hold true for syphilis and HIV despite the overlapping risk factors for infection. Failure to test for syphilis and HIV in the ED is a missed opportunity that can contribute to delay in diagnosis, treatment, and/or linkage to medical care and has public health implications.

Before our intervention, syphilis and HIV testing in the OSUWMC Hospital East ED was remarkably low (Fig. 1). Survey results demonstrated that the major barrier to testing was concerns regarding follow-up of positive results and linkage to care. The inherent algorithmic complexity of available syphilis and HIV tests can also be problematic in an acute and fast-paced setting such as the ED. For example, although we use a rapid fourth-generation HIV-1/HIV-2 Ag/Ab assay as the initial screening test, confirmatory testing (e.g., HIV-1/HIV-2 antibody differentiation and HIV-1 RNA polymerase chain reaction) can take several days to result. In the case of syphilis testing, particularly with reverse sequence screening that uses an initial syphilis antibody, there is often a 2- to 4-day turnaround time for the reflex RPR or TP-PA to result, and even then these can be challenging to interpret by the EM providers who may not be familiar with the algorithms or if prior testing and treatment records are not readily available for review. The usual OSUWMC Hospital East ED protocol for relaying pending STI results to patients (such as for chlamydia and gonorrhea) is via a letter sent by mail, as many patients may have already received empiric treatment during their visit. However, because of the more sensitive and complex

| Age, y | Sex | Race | RPR Titer | Diagnosis | Received Treatment? |
|--------|-----|------|-----------|-----------|---------------------|
| 34     | F   | White | 1:2       | Late latent | Yes                |
| 34     | M   | Black | 1:64      | Secondary  | Yes                |
| 32     | F   | Black | 1:128     | Late latent| Partial            |
| 37     | F   | Black | 1:16      | Secondary  | Yes                |
| 54     | M   | Black | NR‡       | Late latent| Partial            |
| 28     | M   | Black | 1:256     | Late latent| Partial            |
| 31     | M   | Black | 1:1       | Late latent| Partial            |
| 27     | M   | Black | 1:128     | Late latent| Yes                |
| 30     | F   | Black | 1:256     | Primary    | Yes                |
| 45     | F   | Black | 1:128     | Late latent| Partial            |
| 18     | M   | Black | NR        | Late latent| Yes                |
| 39     | F   | Black | 1:1       | Late latent| Yes                |
| 46     | M   | Black | 1:8       | Late latent| Yes                |
| 53     | F   | Black | 1:2       | Late latent| Yes                |
| 33     | F   | Black | NR        | Late latent| No                 |
| 24     | M   | Black | 1:64      | Late latent| No                 |
| 43     | M   | Other | 1:4       | Late latent| No                 |
| 53     | F   | Black | NR        | Late latent| No                 |
| 25     | M   | Black | NR        | Late latent| No                 |
| 56     | M   | Black | NR        | Late latent| No                 |
| 31     | F   | White | 1:16      | Late latent| No                 |
| 41     | F   | Black | NR        | Late latent| No                 |
| 25     | M   | Black | 1:32      | Late latent| No                 |
| 30     | M   | White | 1:2       | Late latent| No                 |
| 57     | M   | Black | NR        | Late latent| No                 |
| 41     | M   | Black | NR        | Late latent| No                 |
| 58     | F   | Black | NR        | Late latent| No                 |
| 51     | F   | Black | NR        | Late latent| No                 |
| 41     | M   | Black | NR        | Late latent| No                 |

*All patients included in the table had reactive syphilis antibody immunoassay results.

†Denotes that patient received at least some treatment of syphilis.

‡NR denotes a nonreactive RPR. All patients with NR RPR had reactive Treponema pallidum particle agglutination assays.

**Figure 1.** Rates of STI Screening in the Emergency Department During the Preintervention Period (January 1, 2012–December 31, 2017) and Postintervention Period (November 1, 2018–November 30, 2019). *Chlamydia, gonorrhea, syphilis, and HIV testing all performed on the same ED visit.
nature of a new HIV diagnosis, direct verbal communication with the patient is preferable so that any questions or concerns can be answered. This could create logistical difficulties for EM providers, as they often work variable hours and may not feel comfortable answering specific questions regarding management and follow-up. In addition, the ability to provide prompt linkage to care is also a concern. Standard referrals placed for an ID clinic appointment may take several weeks to schedule, and prior studies have shown that longer wait times for appointments increase the risk that the patient will be lost to follow-up.

Despite significant improvements in the number of people who were screened for HIV and syphilis during the postintervention period, there are still a substantial proportion of people who are still only being screened for gonorrhea or chlamydia without also being screened for HIV and syphilis. Further investigation into ongoing barriers is needed, particularly to assess whether the discrepancies can be accounted for by variations in individual clinician’s practices or whether there may be patient-specific barriers (such as an unwillingness to undergo venipuncture). The current use of the “STI order set” is optional, and clinicians are able to order individual STI tests without using the order set. One proposed solution would be to create an alternative type of order panel in which the ordering of any one STI test would automatically pull in the orders for the other tests and would require clinicians to manually opt out of orders for comprehensive testing depending on individual circumstances.

Of the 7 new HIV diagnoses identified in the ED during the postintervention period, successful linkage to care and initiation of ART was achieved in most of these patients within 1 to 15 days (median, 6 days) of their ED visit. These findings underscore the fact that involvement of ID providers in the follow-up of patients who tested negative for syphilis (including those with a positive gonorrhea or chlamydia test result) were not available. Rates of chlamydia and gonorrhea testing remained stable between the preintervention and postintervention time periods. The postintervention time period was associated with an increased likelihood of a positive gonorrhea test result, but not a positive chlamydia test result. These findings correlate with a general increased incidence of gonorrhea infection seen in the community during this time.

Despite an increase in the number of patients who were treated for syphilis during the postintervention period, overall follow-up was suboptimal. Treatment for patients with primary and secondary syphilis was very effective, primarily because most of these patients had symptoms that led to a clinical diagnosis and therefore received empiric treatment in the ED before discharge. For those patients who were diagnosed with late-latent syphilis, the rates of follow-up and treatment were lower. Several patients were unable to be reached despite assistance from the local health department disease intervention specialist. Other centers have successfully used point-of-care (POC) testing, where tests results were available before the patient was discharged. This strategy could potentially alleviate some of the difficulty with follow-up, particularly for asymptomatic patients.

Of the HIV-negative patients with positive syphilis antibody test results during the postintervention period, less than half were referred for evaluation for PrEP. Because there is an association between syphilis infection and future risk of HIV acquisition, patients who test positive for syphilis infection are a high-priority group that should be referred for or offered HIV PrEP. Data pertaining to the number of patients who were referred for PrEP who tested negative for syphilis (including those with a positive gonorrhea or chlamydia test result) were not available.

Rates of chlamydia and gonorrhea testing remained stable between the preintervention and postintervention time periods. The postintervention time period was associated with an increased likelihood of a positive gonorrhea test result, but not a positive chlamydia test result. These findings correlate with a general increased incidence of gonorrhea infection seen in the community during this time. Although there was an increase in extragenital gonorrhea/chlamydia testing during the postintervention period, the rates continue to remain very low, with less than 5% of chlamydia or gonorrhea tests performed at any extragenital site. Promoting patient self-collection of pharyngeal and rectal swabs for gonorrhea/chlamydia testing in the ED may help increase extragenital testing rates. Further work is needed to identify additional barriers and improve testing rates, as patients with oral and/or rectal infections may often have negative urine/cervical/urethral testing depending on sexual practices.

Study limitations include the absence of clear follow-up data for patients with positive syphilis and HIV test results during the postintervention period. For this particular study, we did not evaluate the specific indications for STI screening, so we were unable to make an assessment on the overall adequacy of screening in the ED. However, we made the assumption that anyone with an indication for gonorrhea or chlamydia would have also had an indication for syphilis and HIV screening, which was the basis for our comparison. Another limitation to our study is that we do not know whether patients who tested positive for gonorrhea or chlamydia (but not syphilis) or those with negative gonorrhea and chlamydia test results, but engage in high-risk sexual practices, were referred for PrEP. Although education about PrEP was provided to all EM providers, and a system for rapid referral for initial PrEP visits at a Federally Qualified Health Center clinic located within the same hospital was put in place, referral rates and show rates were low overall. Further work will be needed to better gauge local PrEP uptake among individuals who present to the ED and are at risk for HIV acquisition. Best practices, including use of patient navigators, will be evaluated in the next phase of this project.

In addition, the reverse sequence screening and fourth-generation HIV-1/HIV-2 Ag/Ab testing platforms used at our institution for syphilis and HIV, respectively, are not POC tests. Therefore,
we do not know if the availability of POC syphilis and HIV tests would have resulted in a similar increase in testing regardless of our designed interventions. Finally, our study took place in an academic institution with a core group of ID providers who have an interest in syphilis and HIV, it is important to note that importantly effort related to this project was supported with funding from a competitive institutional grant program. Therefore, our findings may not be generalizable to institutions that do not have providers or institutional specific disease intervention specialists who can shoulder some or all of the aforementioned responsibilities.

In conclusion, findings from this study demonstrate that incorporating ID providers to facilitate timely follow-up of syphilis and HIV test results ordered by EM providers can result in a substantial increase in the number of patients who are tested, with increased case finding. Additional studies looking at how the collaboration between ID and EM providers can improve the management and follow-up of patients who are tested for syphilis and HIV in the ED are needed.

REFERENCES

1. Centers for Disease Control and Prevention. Diagnosis of HIV infection in the United States and dependent areas, 2018 (updated). HIV Surveillance Report 2020; 31.
2. Centers for Disease Control and Prevention. Sexually transmitted infections, prevalence, incidence, and cost estimates in the United States 2021. Available at: https://www.cdc.gov/nchhstp/newsroom/2021/2018-std-incidence-prevalence-estimates.html. Accessed February 12, 2021.
3. Hall HI, An Q, Tang T, et al. Prevalence of diagnosed and undiagnosed HIV infection—United States, 2008–2012. MMWR Morb Mortal Wkly Rep 2015; 64:657–662.
4. INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373:795–807.
5. Rodger AJ, Cambiano V, Braun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): Final results of a multicentre, prospective, observational study. Lancet 2019; 393:2428–2438.
6. Syphilis Outbreak Quarterly Report. Columbus Public Health February 2019. Available at: https://www.columbus.gov/publichealth/programs/Office-of-Epidemiology/Sexually-Transmitted-Infections/. Accessed February 12, 2021.
7. Wu MY, Gong HZ, Hu KR, et al. Effect of syphilis infection on HIV acquisition: A systematic review and meta-analysis. Sex Transm Infect 2021; 97:525–533.
8. Pearson WS, Peterman TA, Gift TL. An increase in sexually transmitted infections seen in US emergency departments. Prev Med 2017; 100:143–144.
9. Klein PW, Martin IB, Quinlivan EB, et al. Missed opportunities for concurrent HIV-STD testing in an academic emergency department. Public Health Rep 2014; 129(Suppl 1):12–20.
10. Arbelaez C, Wright EA, Losina E, et al. Emergency provider attitudes and barriers to universal HIV testing in the emergency department. J Emerg Med 2012; 42:7–14.
11. Hecht CR, Smith MD, Radonich K, et al. A comparison of patient and staff attitudes about emergency department-based HIV testing in 2 urban hospitals. Ann Emerg Med 2011; 58(1 Suppl 1):S28–S32.e1–4.
12. Rizza SA, MacGowan RJ, Purcell DW, et al. HIV screening in the health care setting: status, barriers, and potential solutions. Mayo Clin Proc 2012; 87:915–924.
13. Gift TL, Hogben M. Emergency department sexually transmitted disease and human immunodeficiency virus screening: findings from a national survey. Acad Emerg Med 2006; 13:993–996.
14. Columbus Public Health. Syphilis Data Brief: Franklin County, Ohio, 2013–2015. Published August 2016
15. Office of Infectious Disease and HIV/AIDS Policy, HHS. Ending the HIV Epidemic: Plan for America. Available at: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/jurisdictions. Accessed February 14, 2021.
16. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64(RR-43):1–137.
17. Lyons MS, Lindsell CJ, Wayne DB, et al. Comparison of missed opportunities for earlier HIV diagnosis in 3 geographically proximate emergency departments. Ann Emerg Med 2011; 58(1 Suppl 1):S17–S22.e1.
18. Liddicoat RV, Horton NJ, Urban R, et al. Assessing missed opportunities for HIV testing in medical settings. J Gen Intern Med 2004; 19:359–356.
19. Mugavero MJ, Lin HY, Allison JJ, et al. Failure to establish HIV care: Characterizing the "no show" phenomenon. Clin Infect Dis 2007; 45:127–130.
20. Koenig SP, Dorvil N, Dévieux JG, et al. Same-day HIV Testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial. PLoS Med 2017; 14e1002357.
21. Lyss S, Couture K, et al. Influence of point-of-care rapid HIV tests and additional testing staff on ordering of HIV tests by providers in a large, urban emergency department. Ann Emerg Med 2004; 44:S56.
22. Fakile YF, Markowitz N, Zhu W, et al. Evaluation of a rapid syphilis test in an emergency department setting in Detroit, Michigan. Sex Transm Dis 2019; 46:429–433.
23. Bristow CC, Klausner JD, Tran A. Clinical test performance of a rapid point-of-care syphilis treponemal antibody test: A systematic review and meta-analysis. Clin Infect Dis 2020; 71(Suppl 1):S52–S57.
24. Centers for Disease Control and Prevention. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States—2017 Update Clinical Practice Guideline. Available at: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf. Published March 2018. Accessed February 12, 2021.
25. Ohio Department of Health, STD Surveillance Program. 2014–2018 Ohio Infectious Diseases Status Report. Gonorrhea. Available at: https://odohigo.gov/wps/portal/gohd/ohd KNOW-our-programs/STD-surveillance/resources/gonorrhoea-five-year-report. Published May 2019. Accessed March 3, 2021.
26. Wilson JD, Wallace HE, Lofthus-Keeling M, et al. Swab-yourself trial with economic monitoring and testing for infections collectively (SYS-TEMATIC) Part 1: A diagnostic accuracy, and cost-effectiveness, study comparing clinician-taken versus self-taken rectal and pharyngeal samples for the diagnosis of gonorrhoea and chlamydia. Clin Infect Dis 2020; ciaa266.
27. Patton ME, Kidd S, Llata E, et al. Extranatal gonorrhoea and chlamydia testing and infection among men who have sex with men—STD Surveillance Network, United States, 2010–2012. Clin Infect Dis 2014; 58:1564–1570.